Shots:
- Merck KGaA to receive up front, additional regulatory, approval, and sales milestone along with royalties on sales of pimasertib and MSC2015103B. The agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of MEK inhibitors
- Day One plans to initiate a P-I/II study to evaluate the safety, tolerability, and preliminary efficacy of pimasertib in combination with DAY101 in patients aged ≥12yrs. with advanced solid tumors with MAPK inhibitors
- Pimasertib and MSC2015103B are oral, highly-selective MEK I/II inhibitors. Pimasertib has been studied in 10+ P-I/II studies in ~900 patients with various tumor types
Click here to read full press release/ article | Ref: Businesswire | Image: Coworking Centrum
The post Merck KGaA Signs an Exclusive Worldwide License Agreement with Day One for Pimasertib and MSC2015103B first appeared on PharmaShots.
